Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
NKG2D CAR-NK
BIOLOGICAL
3 trials
Sponsors
Zhejiang University
, Hangzhou Cheetah Cell Therapeutics Co., Ltd
Conditions
AML
Ovarian Cancer
Refractory Metastatic Colorectal Cancer
Phase 1
NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
Recruiting
NCT05213195
Zhejiang University
Refractory Metastatic Colorectal Cancer
Start: 2021-12-10
End: 2025-06-30
Target: 38
Updated: 2024-02-12
Unknown Phase
NKG2D CAR-NK & r/rAML
NCT05734898
Zhejiang University
AML
Start: 2023-03-31
End: 2024-09-30
Target: 30
Updated: 2023-03-03
NKG2D CAR-NK & Ovarian Cancer
NCT05776355
Hangzhou Cheetah Cell Therapeutics Co., Ltd
Ovarian Cancer
Start: 2023-03-31
End: 2024-09-30
Target: 18
Updated: 2023-03-28
Related Papers
NKG2D CAR-NK adoptive cellular immunotherapy combined with or without PD-1 blockade in the treatment of patients with metastatic colorectal cancer: an exploratory study.
2025-10-21
2 citations
Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8<sup>+</sup> T cell activation in patients with advanced colorectal cancer.
2025-05-27
7 citations